4Marcellin P, Cheinquer H, Curescu M, et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials [ J ]. Hepatology, 2012, 56 ( 6 ) : 2039- 2050.
5Brochot E, Riachi G, Plantier JC, et al. Kinetics of relapse "after pegylated interferon and ribavirin therapy for chronic hepatitis C [J]. JMedVirol, 2013, 85(7) :1191-1198.
6Kurosaki M, Hiramatsu N, Sakamoto M, et al. Age and total ribavirin dose are independent predictors of relapse after interferon therapy in chronic hepatitis C revealed by data mining analysis [J]. Antivirther, 2012, 17(1):35-43.
7Shin SR, Sinn DH, Gwak GY, et al. Risk factors for relapse in chronic hepatitis C patients who have achieved end of treatment response [ J ]. J Gastroenterol Hepatol, 2010, 25 (5) :957-963.
8Lin KH, Yu HC, Hsu PI, et al. Baseline high viral load and unfavorable patterns of alanine aminotransferase change predict virological relapse in patients with chronic hepatitis C genotype 1 or 2 obtaining rapid virological response during antiviral therapy [J]. HepatMon, 2013, 13(10):e11892.
9Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party, McCaughan GW, Omata M, et al. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and tatmcnt of hepatitis C virus infection[J]. J Gastroentero! Hepatol, 2007, 22 (5) :615-633.
10Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in Patients with HCV genotype ! who relapsed after previous therapy: aphase 3 trial [ J ]. Gastroenterology, 2014, 146 ( 7 ) : 1669-1679.
